Aminophylline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aminophylline: From Bronchospasm to Migraine Disorder
One-Sentence Summary
Aminophylline is a methylxanthine compound historically established as a bronchodilator and treatment for apnea of prematurity, acting through adenosine receptor antagonism and phosphodiesterase inhibition. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 6 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bronchospasm; Apnea of Prematurity |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L4 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data from DrugBank is not available for this report. Based on known information from published literature and clinical context, aminophylline is a methylxanthine derivative (theophylline + ethylenediamine) that acts primarily as a non-selective adenosine receptor antagonist and phosphodiesterase inhibitor. Its efficacy as a bronchodilator and for post-dural puncture headache is well established, and mechanistically this profile may extend to migraine disorder.
The biological link between aminophylline and migraine rests on the adenosine hypothesis of migraine. Accumulating evidence suggests that pathologically elevated adenosine levels in the brain — potentially reflecting impaired cerebral energy metabolism — drive intracranial vasodilation and nociceptive sensitization that underlie migraine attacks. Aminophylline, as an adenosine receptor antagonist, could directly block this pathway. Indirect support comes from caffeine, a structurally related methylxanthine that is already incorporated into established migraine combination products and is recommended for treating post-lumbar puncture headache — a headache phenotype with similar adenosine-mediated vasodilatory mechanisms.
A 2023 review (PMID 38059379) directly proposed aminophylline as a candidate for migraine based on this mechanistic framework, and a 2022 case report (PMID 34308528) documented that aminophylline and caffeine effectively reversed hemiplegic migraine triggered by regadenoson, an adenosine A2A receptor agonist — providing direct pharmacological proof of concept. However, the evidence base currently comprises only mechanistic and observational data; no randomised controlled trial has been conducted.
Clinical Trial Evidence
Currently no related clinical trials for aminophylline in migraine disorder are registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38059379 | 2023 | Review/Clinical Report | Pain Management | Proposes aminophylline as an adenosine receptor antagonist for migraine and pain; reviews evidence for strong therapeutic relief in post-dural headache and observational case series data in migraine |
| 34308528 | 2022 | Case Report | Journal of Nuclear Cardiology | Regadenoson (A2A adenosine agonist) triggered hemiplegic migraine during cardiac stress imaging; aminophylline and caffeine effectively reversed the episode — direct pharmacological proof of concept |
| 7728647 | 1995 | Case Report | Canadian Journal of Cardiology | Syndrome X patient with adenosine-mediated chest pain and migraine-like vascular phenomena; documents adenosine excess as a shared pathophysiological trigger |
| 219563 | 1979 | In Vitro | Stroke | Adenosine and adenine compounds markedly dilated human and feline pial (intracranial) but not extracranial arteries in vitro — mechanistic basis for selective intracranial involvement in adenosine-driven migraine |
New Zealand Market Information
Aminophylline currently has no regulatory authorisations in New Zealand. It is not marketed in this jurisdiction.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic hypothesis linking aminophylline's adenosine antagonism to migraine pathophysiology is biologically plausible and supported by the known efficacy of related methylxanthines (caffeine) in migraine management; however, evidence is currently limited to a single 2023 review article and isolated case reports (L4), with no registered clinical trials and no controlled human efficacy data. The drug is also not marketed in New Zealand, and complete safety information (package insert warnings, contraindications) remains unavailable for formal evaluation.
To proceed, the following is needed:
- Safety profile clarification: Obtain and review the full package insert (warnings, contraindications, drug interactions) before any clinical planning — this is currently a blocking data gap
- MOA documentation: Confirm pharmacodynamic data via DrugBank or primary literature to support the adenosine antagonism hypothesis formally
- Proof-of-concept study: A small prospective observational study or open-label pilot in acute migraine patients is the minimum required to move from L4 to L3 evidence
- Dose and route assessment: Define clinically feasible dosing and administration route for migraine (oral aminophylline vs. IV) given existing PK data
- Regulatory pathway: Assess requirements for a new indication filing in New Zealand given the current zero-authorisation status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.